Aspirin Does NOT Provide Adequate Primary Protection Against DVT in Men Over 65
Aspirin should not be used as primary prophylaxis for deep vein thrombosis in adult males over 65 years old. While aspirin has some antithrombotic activity, it is significantly inferior to standard anticoagulants for preventing DVT and should only be considered in very limited circumstances.
Primary Prevention: Aspirin is Inadequate
The 2021 CHEST guidelines make clear that aspirin is substantially less effective than anticoagulants for VTE prevention 1. When extended anticoagulation is indicated, the guidelines strongly recommend reduced-dose DOACs over aspirin (strong recommendation) 1. This reflects aspirin's inferior efficacy in preventing venous thromboembolism.
Recent high-quality evidence confirms this limitation:
A 2023 meta-analysis of 29,522 patients undergoing major orthopedic surgery found aspirin resulted in 45% higher VTE incidence compared to other anticoagulants (RR=1.45,95% CI 1.18-1.77) and 19% higher rates of proximal DVT/PE (RR=1.19,95% CI 1.02-1.39) 2
A 2025 Japanese study of proximal femoral fracture patients over 65 showed no protective effect of aspirin against DVT (OR: 0.81,95% CI 0.49-1.36, p=0.44) 3
The Only Appropriate Role: Secondary Prevention When Stopping Anticoagulation
Aspirin has one narrow indication: If a patient with unprovoked proximal DVT or PE is stopping anticoagulant therapy and has no contraindication to aspirin, then aspirin is suggested over no therapy to reduce recurrence risk 1. This is a weak recommendation based on low-certainty evidence.
Critical caveats:
- This applies ONLY to secondary prevention (preventing recurrence after a prior DVT)
- This applies ONLY when the patient has already decided to stop anticoagulation
- Aspirin is NOT a reasonable alternative to anticoagulants in patients who can tolerate extended therapy 1
Context-Specific Considerations
Post-Surgical Prophylaxis
In hip arthroplasty specifically, aspirin may be non-inferior when used in sequential protocols (e.g., after initial 5-day rivaroxaban course) 4, but not as sole primary prophylaxis from day 0. The 2026 structured review emphasizes that aspirin should not be used universally as sole primary prophylaxis, especially during the early postoperative hypercoagulable phase 4.
Age-Related Bleeding Risk
The FDA label warns that bleeding risk is higher in patients age 60 or older 5, which is particularly relevant for your patient population over 65. This elevated bleeding risk does not offset aspirin's inferior efficacy for DVT prevention.
Clinical Algorithm
For primary DVT prevention in men >65:
- Use standard anticoagulation (LMWH, DOACs, or warfarin) based on clinical indication
- Do NOT substitute aspirin for anticoagulation
- Consider aspirin ONLY if:
- Patient has prior unprovoked DVT/PE AND
- Patient is stopping anticoagulation (not as alternative to it) AND
- No aspirin contraindications exist
The evidence consistently demonstrates aspirin's inferiority for primary DVT prevention, with multiple recent studies showing either no benefit or significantly worse outcomes compared to standard anticoagulants 3, 2, 4.